VERA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Vera Therapeutics (VERA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows positive technical indicators, strong analyst support with high price targets, and recent insider and institutional interest. Despite some insider selling, the long-term growth potential of its drug pipeline and favorable market sentiment make it a compelling investment opportunity.
The stock's technical indicators are bullish. The MACD histogram is positive and expanding, indicating upward momentum. The RSI is neutral at 50.494, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are: Pivot: 40.095, R1: 42.089, S1: 38.101, R2: 43.321, S2: 36.869.
Wolfe Research upgraded the stock to Outperform with an $88 price target, citing a compelling valuation and large market potential.
BofA reiterated a Buy rating, projecting $2.2B in peak sales for atacicept.
H.C. Wainwright raised the price target to $110, highlighting the priority review granted to atacicept.
Integral Health Asset Management increased its stake in VERA, signaling institutional confidence.
Recent appointment of a Chief Legal Officer to strengthen the company's legal capabilities ahead of atacicept's launch.
Insider selling has increased by 158.76% over the last month, which could indicate caution among company insiders.
Pre-market price is down by 1.49%, reflecting short-term bearish sentiment.
Hedge funds remain neutral, with no significant trading trends over the last quarter.
In Q4 2025, Vera Therapeutics reported no revenue growth (0% YoY), but significant improvements in net income (-$91.1M, up 109.78% YoY) and EPS (-1.39, up 93.06% YoY). While the company is not yet profitable, these improvements indicate progress in reducing losses.
Analysts are highly optimistic about VERA. Wolfe Research upgraded the stock with an $88 price target, citing a compelling valuation and large market potential. BofA reiterated a Buy rating, projecting $2.2B in peak sales for atacicept. H.C. Wainwright raised its price target to $110, highlighting the priority review granted to atacicept.
